Research Money in Economic Stimulus Package Available for Lupus

The National Institutes of Health (NIH) is reserving $200 million of its economic stimulus funding from the "American Recovery and Reinvestment Act of 2009," which was signed by President Barack Obama on February 17, to support approximately 200 Challenge Grants in Health and Science Research.

The deadline for electronic grant applications is April 27, 2009. Successful grantees are expected to receive funding by September 30.  Budgets are limited to $500,000 per year for a two-year maximum total of $1 million.

The Challenge Grants fall within 15 broad areas that range from "Biomarker Discovery and Validation" to "Genomics" and "Enhancing Clinical Trials."

A number of the grants have potentially direct relevance to lupus, such as:

03-AG-104 Biomarkers, stress, and immune function. Identification of biomarkers to assess the impact of stress, both social and biological, on immune function...

03-CA-108 Biomarker Discovery and Validation among racial and ethnic minority Populations. Support community-targeted prevalence studies in co-morbidities (co-occurring conditions) and design research pilots to educate and engage these communities in participating in studies to identify and validate biomarkers of stress-related changes in immune function. Link the value of this research to the health of the community...

04-AR-101* Autoimmunity for Diseases of the Skin, Joints, Muscle and other Tissues. Develop reagents and analytic methods to identify, characterize, track, and inhibit human B and T cells specific for defined self-antigens, and antigen-presenting cells in diseases of the skin, joints, and other tissues. Define mechanisms by which autoreactive lymphocytes contribute to tissue damage...

04-AR-103 Targets for Intervention in Chronic Pain in Musculoskeletal, Skin and Rheumatic Diseases. There is significant variability in the amount of pain individuals experience in spite of having the same degree of the tissue injury and destruction due to chronic disease...

04-MD-101* Development of effective approaches to increase minority recruitment and retention into clinical trials...

05-AR-101* Comparativeness Effectiveness (CE) of Biologics in Autoimmune Rheumatic and Skin Diseases. Create a research structure to study clinical and cost-effectiveness of biologics to determine the best therapy for individual patients...

05-MD-104* Screening of Health Disparity Conditions. Comparing different screening approaches for diseases with increased prevalence in disparity groups with the goal to inform and determine the most effective modality that will result in reduced morbidity and mortality and improved survival rates in different disparity groups.

07-AR-101 Modeling Clinical Trials in Rheumatic, Skin and Musculoskeletal Diseases. Promote the development of computer models to assess the influence of prevention and treatment strategies on outcomes and cost effectiveness in common chronic diseases

06-HL-105 Develop transgenic animal models that are informative for understanding chronic inflammation in humans...

06-AR-103 Systems Biology for Skin and Rheumatic Diseases. Expansion of Merck's proposed Integrative Bionetwork Community to include skin biology and diseases and rheumatic diseases.

08-AR-102 Gene Environment Interactions in Autoimmune Disease. Explore the contribution and mechanisms mediating the contribution of gene-environment interactions in autoimmune disease onset and progression...

15-HL-102 Develop New Therapeutic Strategies for Heart, Lung, and Blood Diseases Based on microRNA Technology. MicroRNAs (miRNA) are involved in regulating gene expression at the post-transcriptional level. About 500 human miRNAs have been discovered...

 

These and other grants are detailed here:

http://grants.nih.gov/grants/funding/challenge_award/Omnibus.pdf

The complete announcement is here:

http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-09-003.html

The following new website at NIH will track developments related to funding provided through the economic stimulus legislation.

http://www.nih.gov/recovery/

 

ALSO: The NIH has posted Recovery Act RFAs and Notices on Shared Instrumentation, Facilities Construction, Renovations, Repair and Improvements:

RFA-RR-09-007 - Recovery Act Limited Competition: Core Facility Renovation, Repair, and Improvement (G20) http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-09-007.html

RFA-RR-09-008 - Recovery Act Limited Competition: Extramural Research Facilities Improvement Program (C06)

http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-09-008.html

PAR-09-118 - Recovery Act Limited Competition:  High-End Instrumentation Grant Program (S10) http://grants.nih.gov/grants/guide/pa-files/PAR-09-118.html

NOT-RR-09-008 - Addition of Recovery Funds to the Shared Instrumentation Grant Program http://grants.nih.gov/grants/guide/notice-files/NOT-RR-09-008.html